These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19707594)

  • 1. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients.
    Fischer K; Pendu R; van Schooten CJ; van Dijk K; Denis CV; van den Berg HM; Lenting PJ
    PLoS One; 2009 Aug; 4(8):e6745. PubMed ID: 19707594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
    Elsheikh E; Lavin M; Heck LA; Larkin N; Mullaney B; Doherty D; Kennedy M; Keenan C; Guest T; O'Mahony B; Fazavana J; Fallon PG; Preston RJS; Gormley J; Ryan K; O'Connell NM; Singleton E; Byrne M; McGowan M; Roche S; Doyle M; Crowley MP; O'Shea SI; Reipert BM; Johnsen JM; Pipe SW; Di Paola J; Turecek PL; O'Donnell JS;
    J Thromb Haemost; 2023 May; 21(5):1123-1134. PubMed ID: 36775768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis.
    Nossent AY; VAN Marion V; VAN Tilburg NH; Rosendaal FR; Bertina RM; VAN Mourik JA; Eikenboom HC
    J Thromb Haemost; 2006 Dec; 4(12):2556-62. PubMed ID: 17059421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
    Swystun LL; Ogiwara K; Rawley O; Brown C; Georgescu I; Hopman W; Labarque V; Male C; Thom K; Blanchette VS; Carcao MD; Lillicrap D
    Blood; 2019 Sep; 134(11):880-891. PubMed ID: 31350267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population.
    Ogiwara K; Swystun LL; Paine AS; Kepa S; Choi SJ; Rejtö J; Hopman W; Pabinger I; Lillicrap D
    J Thromb Haemost; 2021 Mar; 19(3):654-663. PubMed ID: 33219619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A.
    Rejtő J; Königsbrügge O; Grilz E; Hofer S; Mauracher LM; Gabler C; Schuster G; Feistritzer C; Sunder-Plaßmann R; Quehenberger P; Gebhart J; Ay C; Pabinger I
    J Thromb Haemost; 2020 May; 18(5):1081-1086. PubMed ID: 32073230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.
    Kepa S; Horvath B; Reitter-Pfoertner S; Schemper M; Quehenberger P; Grundbichler M; Heistinger M; Neumeister P; Mannhalter C; Pabinger I
    Haemophilia; 2015 May; 21(3):343-350. PubMed ID: 25582282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
    Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
    Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms.
    Albánez S; Ogiwara K; Michels A; Hopman W; Grabell J; James P; Lillicrap D
    J Thromb Haemost; 2016 May; 14(5):953-63. PubMed ID: 26875505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
    Lalezari S; Martinowitz U; Windyga J; Enriquez MM; Delesen H; Schwartz L; Scharrer I
    Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ABO blood group on haemostatic parameters in severe haemophilia A patients performing acute moderate-intensity exercise.
    Merlen C; Zourikian N; Bonnefoy A; Dubé E; Thibeault C; St-Louis J; Rivard GE
    Blood Coagul Fibrinolysis; 2018 Nov; 29(7):626-635. PubMed ID: 30036280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.
    Chen ZP; Li PJ; Li G; Tang L; Zhen YZ; Wu XY; Cheng XL; Luke KH; Blanchette VS; Poon MC; Ding QL; Wu RH
    Chin Med J (Engl); 2018 Aug; 131(15):1780-1785. PubMed ID: 29848837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A.
    Vlot AJ; Mauser-Bunschoten EP; Zarkova AG; Haan E; Kruitwagen CL; Sixma JJ; van den Berg HM
    Thromb Haemost; 2000 Jan; 83(1):65-9. PubMed ID: 10669157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between ABO blood groups and von Willebrand factor, ADAMTS13 and factor VIII in patients undergoing hemodialysis.
    Rios DR; Fernandes AP; Figueiredo RC; Guimarães DA; Ferreira CN; Simões E Silva AC; Carvalho MG; Gomes KB; Dusse LM
    J Thromb Thrombolysis; 2012 May; 33(4):416-21. PubMed ID: 22466813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients.
    van Moort I; Bukkems LH; Heijdra JM; Schutgens REG; Laros-van Gorkom BAP; Nieuwenhuizen L; van der Meer FJM; Fijnvandraat K; Ypma P; de Maat MPM; Leebeek FWG; Meijer K; Eikenboom J; Mathôt RAA; Cnossen MH;
    Thromb Haemost; 2020 Jul; 120(7):1056-1065. PubMed ID: 32480417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity.
    Swystun LL; Lai JD; Notley C; Georgescu I; Paine AS; Mewburn J; Nesbitt K; Schledzewski K; Géraud C; Kzhyshkowska J; Goerdt S; Hopman W; Montgomery RR; James PD; Lillicrap D
    J Clin Invest; 2018 Aug; 128(9):4057-4073. PubMed ID: 30124466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.
    Turecek PL; Johnsen JM; Pipe SW; O'Donnell JS;
    Haemophilia; 2020 Jul; 26(4):575-583. PubMed ID: 32596930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.